TMCnet News
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung CancerMedia Release
SYDNEY, AUSTRALIA, March 30, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line non- small cell lung cancer (1L NSCLC). INSIGHT-003 recently reached its initial enrolment target of 20 patients and will now be expanded to 50 patients across multiple sites. This expansion is based on favourable safety and strong initial efficacy results presented at SITC 2022. Additional data from INSIGHT-003 is expected throughout calendar year 2023. Prof. Dr. Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF and lead investigator noted: “We’re thrilled to expand the trial population for this triple combination therapy, which has demonstrated promising efficacy and safety in 1st line non-small cell lung cancer patients. We have seen the previous findings that are indicative of powerful synergies of efti’s immune system stimulation with anti-PD-(L)1 therapies and separately with chemotherapy across various solid tumors. As we continue to gather clinical data throughout the year, we eagerly anticipate discovering how this synergy translates in the INSIGHT-003 study, which combines all three modalities.” Initial results from the triple combination of efti, an anti-PD-1 therapy and chemotherapy in patients with 1L NSCLC show that the therapy is wel-tolerated and provides promising early signals of therapeutic activity with an ORR of 72.7% and a Disease Control Rate (DCR) of 90.9%. Additionally, 82% of the eleven evaluable patients had a PD-L1 Tumour Proportion Score (TPS) of <50% and this group reported an encouraging 66.7% ORR and 88.9% DCR. Patients with low to negative PD-L1 expression represent two-thirds of the 1L NSCLC patient population and are less responsive to anti-PD-(L)1 therapy compared to patients with a PD-L1 TPS of =50%. Unlike many dual immuno-oncology combinations (IO-IO) that focus solely on high PD-L1 expressing patients, compelling clinical results to date suggest that efti may be uniquely positioned to address the entire NSCLC patient population regardless of PD-L1 expression through chemo-free IO-IO combinations or IO-IO-chemo triple combinations as INSIGHT-003 is evaluating. In addition to the Company’s late-stage clinical development efforts focused on 1L NSCLC with the combination of efti and anti-PD-1 therapy (IO-IO), the expansion of INSIGHT-003 will further inform planning for registrational studies. Importantly, this multi-center investigator-initiated trial will generate valuable data in a cost-efficient manner. Immutep CEO, Marc Voigt, said: “We are grateful for the long-standing support of Dr. Al-Batran and the entire team at IKF. Our valuable relationship with this world-class institution has uncovered many positive attributes of efti and continues to help us cost-effectively advance this novel immunotherapy for patients with advanced solid tumours, including 1st line non-small cell lung cancer.” About INSIGHT-003 About Eftilagimod Alpha (Efti) Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). About Immutep Australian Investors/Media: U.S. Media:
|
